There are a lot of myths in the stem cell field, some even embraced by some stem cell scientists such as the notion that teratoma are always benign. But when we start talking about translating stem cell technology into the clinic, to the bedside, it is especially important to cast aside our myths, no […]
Myth of Perfect Stem Cell: meaning for ACT, Geron and field Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
What’s going on with legislation on ES cell research in Minnesota? I blogged before about how Oklahoma legislators were heading toward passing legislation that would make it a crime to do ES cell research. Unfortunately, that legislation just passed. As if that were not bad enough, now potentially life saving research in Minnesota is starting
Opponents of ES cell research launch stealth attack in Minnesota Read More »
How is Geron doing along with other stem cell biotechs? What’s going on these days with biotech companies working on stem cell-based products? Geron and ACT Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they
Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »
What makes stem cells different? The stem cell field is faced with a dilemma as stem cells and some non-stem cells are sometimes too similar to tell apart. Even worse, stem cells and cancer cells are especially similar. If one focuses specifically on cancer stem cells (aka tumor initiating cells), the similarity between cancer stem
What makes stem cells different? Read More »